Boundless Bio, Company Insiders
BOLD Stock | USD 9.05 0.95 9.50% |
Boundless Bio,'s insiders are aggressively buying. The analysis of insiders' sentiment of trading Boundless Bio, Common stock suggests that all insiders are extremely bullish at this time. Boundless Bio, employs about 72 people. The company is managed by 33 executives with a total tenure of roughly 159 years, averaging almost 4.0 years of service per executive, having 2.18 employees per reported executive.
Matthew Patterson CEO President CEO, Co-Founder, Director |
Jonathan Silverstein Chairman Chairman of the Board |
Boundless Bio,'s Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-04-02 | Ra Capital Management, L.P. | Acquired 312500 @ 16 | View |
Monitoring Boundless Bio,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Boundless |
Boundless Bio, Management Team Effectiveness
The company has return on total asset (ROA) of (0.3313) % which means that it has lost $0.3313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5293) %, meaning that it created substantial loss on money invested by shareholders. Boundless Bio,'s management efficiency ratios could be used to measure how well Boundless Bio, manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.41, whereas Return On Tangible Assets are forecasted to decline to (0.40). At present, Boundless Bio,'s Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 2.02, whereas Non Currrent Assets Other are forecasted to decline to about 527.2 K.The current year's Common Stock Shares Outstanding is expected to grow to about 27.1 M
Boundless Bio, Workforce Comparison
Boundless Bio, Common is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 725. Boundless Bio, holds roughly 72.0 in number of employees claiming about 10% of stocks in Biotechnology industry.
Boundless Bio, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Boundless Bio, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Boundless Bio,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Boundless Bio, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Thomas Soloway over two weeks ago Disposition of 8681 shares by Thomas Soloway of Boundless Bio at 59.37 subject to Rule 16b-3 |
Boundless Bio, Notable Stakeholders
A Boundless Bio, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Boundless Bio, often face trade-offs trying to please all of them. Boundless Bio,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Boundless Bio,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Matthew Patterson | President CEO, Co-Founder, Director | Profile | |
Zachary Hornby | President CEO | Profile | |
Jonathan Silverstein | Chairman of the Board | Profile | |
Jonathan MD | CoFounder Chairman | Profile | |
Thomas Soloway | CFO, Senior Vice President | Profile | |
Fulvio Mavilio | Senior Vice President - Translational Science | Profile | |
Mark Meltz | Senior Vice President General Counsel | Profile | |
Edward Conner | Senior Vice President and Chief Medical Officer | Profile | |
David Nagler | Senior Vice President - Human Resources and Corporate Affairs | Profile | |
John Gray | Senior Vice President - Research and Development | Profile | |
Suyash Prasad | Senior Vice President Chief Medical Officer | Profile | |
Sarah Spencer | Vice President Corporate Communications | Profile | |
Natalie Holles | COO, Senior Vice President | Profile | |
Eric Mosbrooker | Senior Vice President and Chief Commercial Officer | Profile | |
Mary Newman | Senior Vice President - Regulatory Affairs | Profile | |
Andrew Chang | Director, Investor Relations | Profile | |
Thomas Woiwode | Independent Director | Profile | |
Jennifer Jarrett | Director | Profile | |
Stephen Squinto | Independent Director | Profile | |
Tom Woiwode | Board Director | Profile | |
Louis Lange | Independent Director | Profile | |
Scott Morrison | Independent Director | Profile | |
Mark Goldberg | Director | Profile | |
Julie Smith | Director | Profile | |
Thomas Schuetz | Board Director | Profile | |
Kush Parmar | Board Director | Profile | |
Christian Hassig | Chief Officer | Profile | |
Jamilu Rubin | Chief Officer | Profile | |
MS MBA | Chief Officer | Profile | |
Meredith Wesley | Senior Culture | Profile | |
Shailaja Kasibhatla | Senior Development | Profile | |
Anthony Pinkerton | Senior Discovery | Profile | |
Jessica JD | Chief Secretary | Profile |
About Boundless Bio, Management Performance
The success or failure of an entity such as Boundless Bio, Common often depends on how effective the management is. Boundless Bio, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Boundless management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Boundless management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.38) | (0.40) | |
Return On Capital Employed | (0.45) | (0.48) | |
Return On Assets | (0.38) | (0.40) | |
Return On Equity | 0.39 | 0.41 |
The data published in Boundless Bio,'s official financial statements usually reflect Boundless Bio,'s business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Boundless Bio, Common. For example, before you start analyzing numbers published by Boundless accountants, it's critical to develop an understanding of what Boundless Bio,'s liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Boundless Bio,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Boundless Bio,'s management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Boundless Bio,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Boundless Bio, Common. Please utilize our Beneish M Score to check the likelihood of Boundless Bio,'s management manipulating its earnings.
Boundless Bio, Workforce Analysis
Traditionally, organizations such as Boundless Bio, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Boundless Bio, within its industry.Boundless Bio, Manpower Efficiency
Return on Boundless Bio, Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 686.6K | |
Net Loss Per Executive | 1.5M | |
Working Capital Per Employee | 1.6M | |
Working Capital Per Executive | 3.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Boundless Stock analysis
When running Boundless Bio,'s price analysis, check to measure Boundless Bio,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio, is operating at the current time. Most of Boundless Bio,'s value examination focuses on studying past and present price action to predict the probability of Boundless Bio,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio,'s price. Additionally, you may evaluate how the addition of Boundless Bio, to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Boundless Bio,'s industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.33) | Return On Equity (0.53) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.